So far, some monoclonal antibodies in CRSwNP have entered clinical application or clinical trial stage to treat nasal polyps, including omalizumab (anti‐IgE), reslizumab (anti‐IL‐5), mepolizumab (anti‐IL‐5) and dupilumab (anti‐IL‐4Rα).132. Here, IL4R is linked to Nasal polyposis.